Avantium intends to list on Euronext Amsterdam

Avantium has announced its intention to raise new funds through an IPO and to apply for a listing on Eurolist by Euronext Amsterdam before the end of the year, subject to market conditions.

Avantium, a spin-off from Royal Dutch Shell in 2000, has developed advanced proprietary high-throughput R&D technology.

This enables it to conduct many automated experiments in parallel on a very small scale, providing fast and cost effective research at superior success rates.

Avantium provides R&D services and tools to more than 70 companies worldwide across the energy, chemicals and pharmaceutical industries including BP, Royal Dutch Shell, Sasol, Pfizer, Boehringer Ingelheim and GlaxoSmithKline.

Funds raised through an IPO will be used to further grow the business by advancing product development in the fields of next generation biofuels and improved forms of existing drugs.

Avantium also announced today breakthrough results of the first engine tests of its novel next generation biofuel with superior economics and properties compared to current biofuels.

Avantium International B.V.

Avantium International B.V.
R&D services

Latest News

Clinical study supports the use of Cheetah Medical's technologies

Cheetah Medical, a leader in non-invasive hemodynamic monitoring, has announced the publication of a major clinical study designed to evaluate stroke volume guided resuscitation in ICU patients with severe sepsis and septic shock

Vertos Medical Secures $28m in Latest Round of Funding

Vertos Medical Inc., a leader in the minimally invasive treatment of lumbar spinal stenosis has announced that it has completed a $28 million financing round.

VitalConnect Announces Closure of $33m Series C Financing

VitalConnect, a leader in medical-grade wearable biosensor systems, has announced that it has closed a Series C Preferred Stock equity financing round of $33 million led by new investors MVM Life Science Partners and Baxter.

Providence Medical Technology announces new equity financing of $10.5 million

Providence Medical Technology, Inc., an innovator in tissue-sparing, cervical-fusion technology, has announced the closing of $10.5 million in new equity financing for the company.

Wilson Therapeutics announces that WTX101 meets the primary endpoint in Phase 2 study in Wilson Disease

Wilson Therapeutics AB has announced that the Phase II study of WTX101 (bis-choline tetrathiomolybdate; Decuperate®), an investigational first in class copper modulating agent with a unique mode of action for the treatment of patients with Wilson Disease, met its primary endpoint.

MVM invests €15.2m in Valneva SE

Valneva SE is a commercial stage vaccine company with products to prevent Japanese encephalitis and cholera